Given the critical role of PDGFs in cancer, targeting the PDGF/PDGFR axis represents a promising therapeutic strategy. Several tyrosine kinase inhibitors (TKIs) that block PDGFR signaling have been developed and are currently being tested in clinical trials. For instance, Imatinib is a well-known TKI that has shown efficacy in treating gastrointestinal stromal tumors (GISTs) and certain types of leukemia by inhibiting PDGFR signaling. Other strategies include monoclonal antibodies that neutralize PDGFs or block their receptors.
